Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 9/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ESRRA | P11474 | 3/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20644392 | 0.83 | OGA (0.41) | EGLN2EGLN1RXRAGRIN1GRIN2B | |
| SCHEMBL19105578 | 0.78 | OPRM1 (0.40) | EGLN2RXRAGRIN1GRIN2BOPRM1 | |
| SCHEMBL24958910 | 0.78 | JAK2 (0.40) | EGLN1ACACB | |
| SCHEMBL25820300 | 0.76 | RXRA (0.39) | EGLN2RXRAGRIN1GRIN2BNOTUM | |
| SCHEMBL13160180 | 0.76 | NOTUM (0.51) | ESRRANOTUM | |
| SCHEMBL20644544 | 0.76 | EGLN2 (0.36) | EGLN2EGLN1RXRAGRIN1GRIN2B | |
| SCHEMBL889374 | 0.75 | GRIA1 (0.43) | EGLN1ACACBNOTUMPANK3 | |
| SCHEMBL20437896 | 0.72 | NOTUM (0.60) | EGLN2EGLN1NOTUM | |
| SCHEMBL15114557 | 0.72 | NOTUM (0.60) | EGLN1NOTUM | |
| SCHEMBL25898936 | 0.72 | ESRRA (0.48) | ESRRANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | EGLN2 1111/4885EGLN1 1460/4885RXRA 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.